Reveals how fulvestrant modifies chromatin dynamics in breast cancer cells, suggesting complex therapeutic effects.
This study provides new insights into the mechanistic impact of FULV on ER activity, highlighting its ability to modulate H3K27ac dynamics even in the absence of transcriptional changes. These findings underscore the complexity of ER signaling and further suggest that FULV's therapeutic effects may extend beyond simple antagonism of ER activity.
No takes yet. Share an insight, caveat, or question.
Barlier et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: